Provectus (PVCT) director awarded Series D-1 convertible preferred stock grant

Rhea-AI Filing Summary

PROVECTUS BIOPHARMACEUTICALS, INC. director John Lacey III reported receiving a grant of 48,917 shares of Series D-1 Convertible Preferred Stock on June 30, 2026. The shares were awarded at a price of $0.00 per share as a compensation-related acquisition.

Each Series D-1 share is convertible into 10 shares of common stock, representing 489,170 underlying common shares for this grant. After this award, Lacey holds 228,509 shares of Series D-1 Convertible Preferred Stock. The Series D-1 preferred will automatically convert into common stock on December 31, 2028, unless converted earlier under its certificate of designation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lacey John III

Role null

Type	Security	Shares	Price	Value
Grant/Award	Series D-1 Convertible Preferred Stock	48,917	$0.00	--

Holdings After Transaction: Series D-1 Convertible Preferred Stock — 228,509 shares (Direct, null)

Footnotes (1)

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Key Figures

Preferred shares granted: 48,917 shares Conversion ratio: 10 common shares per preferred share Underlying common shares: 489,170 shares +3 more

6 metrics

Preferred shares granted 48,917 shares Series D-1 Convertible Preferred Stock granted on June 30, 2026

Conversion ratio 10 common shares per preferred share Series D-1 Convertible Preferred Stock terms

Underlying common shares 489,170 shares Common stock underlying 48,917 Series D-1 preferred shares

Preferred holdings after grant 228,509 shares Series D-1 Convertible Preferred held after transaction

Grant price per share $0.00 per share Series D-1 Convertible Preferred Stock award

Automatic conversion date December 31, 2028 Series D-1 Convertible Preferred automatic conversion into common stock

Key Terms

Series D-1 Convertible Preferred Stock, convertible, Certificate of Designation

3 terms

Series D-1 Convertible Preferred Stock financial

"Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock"

convertible financial

"Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock"

A convertible is a type of investment that starts as a loan or preferred stake (like a bond or preferred share) but can be exchanged for common shares of the company at a set price or under certain conditions. It matters to investors because it offers a mix of steady income and downside protection like a loan, plus the upside of stock ownership if the company does well—similar to holding a coupon that you can trade for a full ticket if the event becomes valuable.

Certificate of Designation regulatory

"in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock"

A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 09:21 PM Accepted by SEC EDGAR 06/30/2026 - 09:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lacey John III

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TENNESSEE 37929

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D-1 Convertible Preferred Stock	(1)	06/30/2026		A		48,917		06/30/2026	(2)	Common Stock	489,170	$0	228,509	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

	/s/ John Lacey III	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PVCT director John Lacey III report?

John Lacey III reported receiving 48,917 shares of Series D-1 Convertible Preferred Stock as a grant. The award was recorded on June 30, 2026 and was acquired at a price of $0.00 per share as compensation.

How many Provectus (PVCT) common shares are underlying the new preferred grant?

The 48,917 Series D-1 Convertible Preferred shares are convertible into 489,170 common shares. Each preferred share converts into 10 common shares under the Series D-1 terms described in the filing’s footnotes.

What are John Lacey III’s Series D-1 Preferred holdings in PVCT after this Form 4?

After the reported grant, John Lacey III holds 228,509 shares of Series D-1 Convertible Preferred Stock. This figure reflects his total Series D-1 preferred position immediately following the June 30, 2026 compensation award.

When will PVCT’s Series D-1 Convertible Preferred Stock automatically convert?

The Series D-1 Convertible Preferred Stock will automatically convert into common stock on December 31, 2028. It may also be converted earlier according to the terms in the Certificate of Designation governing the Series D-1 shares.

Was the PVCT insider transaction a market purchase or a compensation grant?

The transaction was a compensation-related grant, not a market purchase. The Form 4 uses code “A” for grant, award, or other acquisition, and the shares were acquired at a price of $0.00 per share as part of an award.